Consolidated Statements of Operations and Comprehensive Loss - USD ($) |
12 Months Ended | |
|---|---|---|
Mar. 31, 2023 |
Mar. 31, 2022 |
|
| Income Statement [Abstract] | ||
| Sales | $ 77,044 | $ 503,906 |
| Cost of sales | (75,328) | (344,300) |
| Cost of sales-inventory write down | (1,478,108) | 0 |
| Gross profit (loss) | (1,476,392) | 159,606 |
| Operating expenses: | ||
| Research and development | 1,538,615 | 1,556,988 |
| General and administrative | 5,600,188 | 6,173,049 |
| Impairment of intangible assets | 980,039 | 0 |
| Total operating expenses | 8,118,842 | 7,730,037 |
| Loss from operations | (9,595,234) | (7,570,431) |
| Interest expense | (6,412,501) | (6,666,630) |
| Change in fair value of warrant liability | 1,864,000 | |
| Loss before income tax benefit | (14,143,735) | (14,237,061) |
| Provision for income tax benefit | 0 | 350,256 |
| Net loss | (14,143,735) | (13,886,805) |
| Other comprehensive income: | ||
| Foreign currency translation adjustment | (836,946) | (257,885) |
| Comprehensive loss | $ (14,980,681) | $ (14,144,690) |